Shelley Ringo, MD
Sports Medicine · Pullman, WANPI 1316143886
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 50 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $279 and has fallen 68.5% since, to $88 in 2024.
Across 50 payments — averaging $15.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$92
- Novo Nordisk$74
- Amgen$72
- Ironshore Pharmaceuticals Inc.$67
- AbbVie$57
- Sanofi-aventis U.S. LLC$55
- plus $357 from 14 others
What the payments were for
- Food & beverage$774100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 6 | $92 |
| Novo Nordisk | 5 | $74 |
| Amgen(2 entities) | 4 | $72 |
| Ironshore Pharmaceuticals Inc. | 3 | $67 |
| AbbVie | 3 | $57 |
| Sanofi-aventis U.S. LLC | 3 | $55 |
| Johnson & Johnson | 4 | $50 |
| Exact Sciences | 3 | $46 |
| Merck | 3 | $44 |
| Pfizer | 3 | $44 |
| Lilly USA, LLC | 3 | $37 |
| Teva Pharmaceuticals USA, Inc. | 2 | $24 |
| Antares Pharma, Inc. | 1 | $18 |
| Bristol Myers Squibb | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
| Corium, LLC | 1 | $13 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $11 |
| Fidia Pharma USA Inc. | 1 | $9 |
How this compares
$774 in reported general payments places this provider in the 55th percentile of 132 sports medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BystolicNebivolol Hcl | 12 | $712 |
| Rosuvastatin Calcium | 57 | $652 |
| Atorvastatin Calcium | 54 | $637 |
| Omeprazole | 30 | $625 |
| Losartan Potassium | 38 | $407 |
| Levothyroxine Sodium | 30 | $334 |
| Celecoxib | 12 | $305 |
| Pantoprazole Sodium | 12 | $296 |
| Gabapentin | 13 | $261 |
| Amlodipine Besylate | 24 | $218 |
| Alendronate Sodium | 22 | $216 |
| Fluoxetine Hcl | 23 | $205 |
| Diclofenac Sodium | 22 | $201 |
| Escitalopram Oxalate | 17 | $195 |
| Lisinopril | 27 | $171 |
Paid to pharmacies, not to this prescriber.
Other sports medicine in Pullman
- Mathew TaylorPullman$36K
- Geoffrey HiggsProsser$569K
- Nicholas KennedyYakima$112K
- Nicholas VaudreuilEverett$49K
- Adam PourchoSeattle$38K
- Christopher WahlIssaquah$37K
- Nicholas WilcoxMarysville$36K
- Brandon NudelmanBellevue$32K
- Judd FitzgeraldKennewick$14K
- Taylor BuuckSeattle$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.